immune system
N |
• mutant mice are viable, fertile and remain healthy up to 60 weeks of age with no signs of acute or chronic infection
• the number and distribution of thymocytes and splenic T cell populations is normal relative to wild-type controls
|
• unlike wild-type mice, mutants fail to form spleen germinal centers after i.p. immunization with sheep red blood cells (SRBCs)
|
• after a 16-hr treatment with LPS (1 ug), mutant thioglycollate-elicited peritoneal macrophages show a significant decrease in IL-1alpha, IL-1beta, and IL-6 levels relative to wild-type macrophages
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• unlike wild-type mice, mutants fail to form germinal centers in Peyer's patches after i.p. immunization with SRBCs
|
• unlike wild-type mice, mutants fail to form germinal centers in mesenteric lymph nodes after i.p. immunization with SRBCs
|
• at 6-8 weeks of age, mutants fail to form germinal centers in peripheral lymphoid organs after i.p. immunization with SRBCs
|
• after challenge with a high dose of LPS (800 ug/mouse), serum levels of IL-1alpha, IL-1beta, IL-6, and IFN-gamma are significantly reduced by 30% to 60% relative to those in similarly treated wild-type mice
|
• whereas all wild-type mice die within 6-9 hrs after injection of 1 ug LPS and 20 mg D-galactosamin (GalN), mutant mice are resistant to endotoxic shock even at 100 ug LPS and 20 mg GalN per mouse
• mutant mice show a lower mortality rate (2 of 5) than wild-type mice (4 of 5) after a high dose injection of LPS (1200 ug/mouse) in the absence of GalN
• unlike wild-type, mutant mice do not exhibit hepatocyte apoptosis or acute hepatitis after a 4-hr treatment with LPS (10 ug/mouse) and GalN (20 mg/mouse)
• however, no differences in thymocyte apoptosis are observed in cortex after a 4-hr treatemnt with LPS (10 ug/mouse) and GalN (20 mg/mouse) or after a 12-hr treatment with a high dose of LPS alone (800 ug/mouse)
|
hematopoietic system
• unlike wild-type mice, mutants fail to form spleen germinal centers after i.p. immunization with sheep red blood cells (SRBCs)
|
• after a 16-hr treatment with LPS (1 ug), mutant thioglycollate-elicited peritoneal macrophages show a significant decrease in IL-1alpha, IL-1beta, and IL-6 levels relative to wild-type macrophages
|
behavior/neurological
• mutant mice spend significantly less time in the open arms relative to wild-type mice; this is ameliorated by diazepam treatment
|
• mutant mice show more frequent, longer grooming episodes than wild-type mice
|
• mutant mice show less rearing episodes than wild-type mice in a novel environment
|
• mutant mice show reduced horizontal activity relative to wild-type mice in the open field test
|
homeostasis/metabolism
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• after challenge with a high dose of LPS (800 ug/mouse)
|
• mutants show an increased level of 5-HT in the hippocampus, medulla oblongata/pons and cerebellum relative to wild-type mice
• increased levels of 5-HIAA are observed in brain
|